Gilead Seen Staying Top Dog In HCV, But Merck Rising

By | November 18, 2015

Scalper1 News

On Wednesday, the morning after the annual Liver Meeting wrapped up in San Francisco, Wall Street analysts sifted through the implications of the data rolled out there for the vast hepatitis C market. Analysts saw continued dominance for Gilead Sciences (GILD) in genotype 1 of the hepatitis C virus (HCV), which accounts for the majority of cases. Gilead’s Harvoni, a combination of sofosbuvir (sold separately as Sovaldi) and ledipasvir, is already Scalper1 News

Scalper1 News